http://synoxtherapeutics.com/synox-therapeutics-further-strengthens-team-with-appointments-of-chief-medical-officer-and-chief-technology-officer/ 2022-07-11T15:08:58+00:00 http://synoxtherapeutics.com/synox-therapeutics-raises-e37m-in-series-a-financing/ 2022-07-11T15:09:37+00:00 http://synoxtherapeutics.com/long-term-clinical-activity-safety-and-patient-reported-quality-of-life-for-emactuzumab-treated-patients-with-diffuse-type-tenosynovial-giant-cell-tumour/ 2022-07-11T18:01:16+00:00 http://synoxtherapeutics.com/csf1r-inhibition-with-emactuzumab-in-locally-advanced-diff-use-type-tenosynovial-giant-cell-tumours-of-the-soft-tissue-a-dose-escalation-and-dose-expansion-phase-1-study/ 2022-07-11T18:02:41+00:00 http://synoxtherapeutics.com/synox-therapeutics-strengthens-team-with-appointment-of-ton-logtenberg-as-chairman-and-ray-barlow-as-chief-executive-officer/ 2022-07-19T15:04:47+00:00 http://synoxtherapeutics.com/synox-therapeutics-to-present-two-posters-at-ctos-2021-virtual-annual-meeting/ 2022-08-31T09:55:21+00:00 http://synoxtherapeutics.com/emactuzumab-designated-as-an-orphan-medicinal-product-in-europe/ 2024-04-22T07:31:22+00:00 http://synoxtherapeutics.com/synox-therapeutics-announces-75m-series-b-round-to-fund-phase-3-trial-of-potential-best-in-class-treatment-for-tgct/ 2024-04-30T07:01:12+00:00 http://synoxtherapeutics.com/synox-therapeutics-further-strengthens-executive-team-with-appointments-of-u-s-based-chief-medical-officer-and-chief-commercial-officer/ 2025-04-01T11:18:57+00:00 http://synoxtherapeutics.com/synox-therapeutics-adds-new-investor-and-capital-to-series-b-financing-raising-total-to-92-million-and-doses-first-patients-in-phase-3-trial/ 2025-04-01T11:20:38+00:00 http://synoxtherapeutics.com/synox-therapeutics-secures-up-to-35m-debt-financing-with-hercules-capital-to-progress-development-and-commercialisation-of-emactuzumab/ 2025-04-01T11:21:47+00:00 http://synoxtherapeutics.com/synox-therapeutics-announces-board-chair-transition-to-align-with-advancing-regulatory-and-commercialization-strategy/ 2025-05-21T13:51:28+00:00 http://synoxtherapeutics.com/synox-therapeutics-completes-enrollment-in-registrational-phase-3-tangent-clinical-trial-significantly-ahead-of-timeline/ 2025-08-05T16:56:48+00:00 http://synoxtherapeutics.com/synox-therapeutics-receives-fast-track-designation-from-u-s-food-and-drug-administration-for-emactuzumab-for-tenosynovial-giant-cell-tumours-tgct/ 2025-10-20T13:48:15+00:00 http://synoxtherapeutics.com/synox-therapeutics-announces-positive-topline-results-from-the-phase-3-tangent-study/ 2026-04-13T06:00:32+00:00 http://synoxtherapeutics.com/synox-therapeutics-strengthens-board-of-directors-with-leading-experts-in-commercialisation-and-corporate-development-amid-continued-corporate-progress/ 2026-04-13T06:09:35+00:00